1. Home
  2. RGCO vs AARD Comparison

RGCO vs AARD Comparison

Compare RGCO & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RGC Resources Inc.

RGCO

RGC Resources Inc.

N/A

Current Price

$22.50

Market Cap

232.9M

Sector

Utilities

ML Signal

N/A

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

HOLD

Current Price

$14.11

Market Cap

231.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGCO
AARD
Founded
1912
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.9M
231.9M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
RGCO
AARD
Price
$22.50
$14.11
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$30.63
AVG Volume (30 Days)
8.8K
194.4K
Earning Date
11-19-2025
11-13-2025
Dividend Yield
3.62%
N/A
EPS Growth
11.26
N/A
EPS
1.29
N/A
Revenue
$95,334,212.00
N/A
Revenue This Year
$9.00
N/A
Revenue Next Year
$8.30
N/A
P/E Ratio
$17.78
N/A
Revenue Growth
12.63
N/A
52 Week Low
$19.06
$4.88
52 Week High
$23.82
$19.58

Technical Indicators

Market Signals
Indicator
RGCO
AARD
Relative Strength Index (RSI) 57.28 68.03
Support Level $21.86 $12.54
Resistance Level $22.42 $14.29
Average True Range (ATR) 0.59 0.95
MACD 0.01 0.57
Stochastic Oscillator 75.37 86.43

Price Performance

Historical Comparison
RGCO
AARD

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: